EP1178829A1 - Menschlicher monoklonaler antikörper - Google Patents
Menschlicher monoklonaler antikörperInfo
- Publication number
- EP1178829A1 EP1178829A1 EP00939304A EP00939304A EP1178829A1 EP 1178829 A1 EP1178829 A1 EP 1178829A1 EP 00939304 A EP00939304 A EP 00939304A EP 00939304 A EP00939304 A EP 00939304A EP 1178829 A1 EP1178829 A1 EP 1178829A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- antibody
- rsv
- human
- antibodies
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 92
- 241000725643 Respiratory syncytial virus Species 0.000 claims abstract description 72
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims description 39
- 239000012634 fragment Substances 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 29
- 241000700605 Viruses Species 0.000 claims description 28
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 27
- 239000000427 antigen Substances 0.000 claims description 27
- 108091007433 antigens Proteins 0.000 claims description 27
- 102000036639 antigens Human genes 0.000 claims description 27
- 230000003472 neutralizing effect Effects 0.000 claims description 27
- 150000007523 nucleic acids Chemical class 0.000 claims description 26
- 239000013612 plasmid Substances 0.000 claims description 19
- 208000015181 infectious disease Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000009169 immunotherapy Methods 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 49
- 102000004169 proteins and genes Human genes 0.000 abstract description 37
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 abstract description 18
- 230000004927 fusion Effects 0.000 abstract description 14
- 230000001225 therapeutic effect Effects 0.000 abstract description 12
- 238000011321 prophylaxis Methods 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 52
- 108060003951 Immunoglobulin Proteins 0.000 description 43
- 102000018358 immunoglobulin Human genes 0.000 description 43
- 150000001413 amino acids Chemical class 0.000 description 41
- 230000027455 binding Effects 0.000 description 36
- 235000018102 proteins Nutrition 0.000 description 36
- 239000013598 vector Substances 0.000 description 34
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 29
- 238000010367 cloning Methods 0.000 description 28
- 238000003752 polymerase chain reaction Methods 0.000 description 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 17
- 238000003556 assay Methods 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 108091026890 Coding region Proteins 0.000 description 11
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 108010076504 Protein Sorting Signals Proteins 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 230000000069 prophylactic effect Effects 0.000 description 9
- 239000012636 effector Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 5
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 5
- 208000035415 Reinfection Diseases 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 229940112129 campath Drugs 0.000 description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 210000004602 germ cell Anatomy 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000000241 respiratory effect Effects 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 206010006448 Bronchiolitis Diseases 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 208000002330 Congenital Heart Defects Diseases 0.000 description 2
- 206010011703 Cyanosis Diseases 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- 241000144282 Sigmodon Species 0.000 description 2
- 230000010530 Virus Neutralization Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 238000009175 antibody therapy Methods 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 208000028831 congenital heart disease Diseases 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- -1 no more than 10) Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229960000329 ribavirin Drugs 0.000 description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000702374 Enterobacteria phage fd Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 241000711920 Human orthopneumovirus Species 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100434885 Mus musculus Ankrd34b gene Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000711902 Pneumovirus Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000144290 Sigmodon hispidus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical group C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000027645 antigenic variation Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000010405 clearance mechanism Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 208000030500 lower respiratory tract disease Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 208000024584 respiratory abnormality Diseases 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000010464 virion assembly Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
Definitions
- This invention relates to novel human monoclonal antibodies ( Abs) and to the genes encoding same. More specifically, this invention relates to human monoclonal antibodies specifically reactive with an epitope of the fusion (F) protein of Respiratory Syncytial Virus (RSV) . Such antibodies are useful for the therapeutic and/or prophylactic treatment of RSV infection in human patients, particularly infants and young children.
- Abs human monoclonal antibodies
- F fusion protein of Respiratory Syncytial Virus
- Respiratory syncytial virus is the major cause of lower respiratory disease in children, giving rise to predictable annual epidemics of bronchiolitis and pneumonia in children worldwide.
- the virus is highly contagious, and infections can occur at any age.
- Comprehensive details concerning RSV infection and its clinical features can be obtained from excellent recent reviews by Mclntosh, K. and R. M. Chanock, In: “Respiratory Syncytial Virus", Ch. 38, B.N. Fields ed. , Raven Press (1990) and Hall, C.B., In: "Textbook of Pediatric Disease” Feigin and Cherry, eds., W.B. Saunders, pgs 1247-1268 (1987) .
- RSV is distributed worldwide.
- Other respiratory viruses cause epidemics at irregular intervals or exhibit a mixed endemic/epidemic pattern, but RSV is the only respiratory viral pathogen that produces a sizable epidemic every year in large urban centers .
- RSV epidemics In the temperate areas of the world, RSV epidemics have occurred primarily in the late fall, winter or spring but never during the summer.
- the occurrence and spread of infection within a community is characteristic and easily diagnosed, leading to sharp rises in cases of bronchiolitis and pediatric pneumonia and the number of hospital admissions of young children with acute lower respiratory tract disease.
- Other respiratory viral agents that occur in outbreaks are rarely present at the same time as RSV.
- mice infected with RSV virus persistently shed virus. These mice can be cured by adoptive transfer of primed T cells [Cannon, M. J. et al . , Immunology 62:133-138 (1987)].
- RSV belonging to the family paramyoxoviridae, is a negative-strand unsegmented RNA virus with properties similar to those of the paramyxoviruses . It has, however been placed in a separate genus Pneumovirus, based on morphologic differences and lack of hemagglutinin and neuraminidase activities. RSV is pleomorphic and ranges in size from 150-300 nm in diameter. The virus matures by budding from the outer membrane of a cell and virions appear as membrane-bound particles with short, closely spaced projections or "spikes". The RNA genome encodes 10 unique viral polypeptides ranging in size from 9.5 kDa to 160 kDa [Huang, Y. T.
- F, G, N, P, L, M, M2 Seven proteins (F, G, and SH) are present in RSV virions and at least three proteins (F, G, and SH) are expressed on the surface of infected cells.
- the F protein [SEQ ID NO : 20] has been conclusively identified as the protein responsible for cell fusion since specific antibodies to this protein inhibit syncytia formation in vi tro and cells infected with vaccinia virus expressing recombinant F protein form syncytia in the absence of other RSV virus proteins. In contrast, antibodies to the G protein do not block syncytia formation but prevent attachment of the virus to cells .
- RSV can be divided into two antigenically distinct subgroups, (A & B) [Mufson, M. A. et al . , J . Gen ' 1. Virol. 66:2111-2124 (1985)]. This antigenic dimorphism is linked primarily to the surface attachment (G) glycoprotein [Johnson, R. A. et al . , Proc. Nat ' 1. Acad. Sci. USA 84:5625-5629 (1987)]. Strains of both group A and B circulate simultaneously, but the proportion of each may vary unpredictably from year to year. An effective therapy must therefore target both subgroups of the virus and this is the reason for the selection of the highly conserved surface fusion (F) protein as target antigen for mAb therapy as will be discussed later.
- a & B antigenically distinct subgroups
- the induction of neutralizing antibodies to RSV virus appears to be limited to the F and G surface glycoproteins .
- the F protein is the major target for cross-reactive neutralizing antibodies associated with protection against different strains of RSV virus.
- experimental vaccination of mice or cotton rats with F protein also results in cross protection.
- the antigenic relatedness of the F protein across strains and subgroups of the virus is reflected in its high degree of homology at the amino acid level.
- antigenic dimorphism was linked primarily to the G glycoprotein .
- the F protein has a predicted molecular weight of 68-70 kDa; a signal peptide at its N-terminus ; a membrane anchor domain at its C terminus; and is cleaved proteolytically in the infected cell prior to virion assembly to yield disulfide linked F 2 and Fi .
- Five neutralizing epitopes have been identified within the F protein sequence [SEQ ID NO: 20] and map to residues 205-225; 259-278; 289- 299; 483-488 and 417-438.
- IVIG intravenous gammaglobulins
- monoclonal antibodies have been employed.
- the advantages of such an approach include: a higher concentration of specific antibody can be achieved thereby reducing the amount of globulin required to be given; the reliance on direct blood products can be eliminated; the levels of antibody in the preparation can be more uniformly controlled and the routes of administration can be extended.
- passive immunotherapy employing monoclonal antibodies from a heterologous species (e.g., murine) has been suggested (See: PCT Application PCT/US94/08699 , Publication No. WO 95/04081)
- one alternative to reduce the risk of an undesirable immune response on the part of the patient directed against the foreign antibody is to employ
- a second and more preferred approach is to employ fully human mABs.
- Unfortunately there have been few successes in producing human monoclonal antibodies through classic hybridoma technology. Indeed, acceptable human fusion partners have not been identified and murine myeloma fusion partners do not work well with human cells, yielding unstable and low producing hybridoma lines.
- recent advances in molecular biology and immunology make it now possible to isolate human mABs, particularly directed against foreign infectious agents .
- this invention provides fully human monoclonal antibodies and functional fragments thereof specifically reactive with an F protein epitope of RSV and capable of neutralizing RSV infection.
- These human mABs specific for the F protein of RSV virus may be useful to passively treat or prevent infection.
- the present invention provides modifications to neutralizing single chain Fv fragments (scFV) specific for the F protein of RSV produced by random combinatorial cloning of human antibody sequences and isolated from a filamentous phage Fab display library.
- scFV single chain Fv fragments
- a reshaped or altered human antibody containing human heavy and light chain constant regions from a first human donor and heavy and light chain variable regions or the CDRs thereof derived from human neutralizing monoclonal antibodies for the F protein of RSV derived from a second human donor.
- the present invention provides a pharmaceutical composition which contains one (or more) altered or reshaped antibodies and a pharmaceutically acceptable carrier.
- the invention provides a pharmaceutical composition comprising at least one dose of an immunotherapeutically effective amount of the reshaped, altered or monoclonal antibody of this invention in combination with at least one additional monoclonal, altered or reshaped antibody.
- the additional antibody is an anti-RSV antibody distinguished from the subject antibody of the invention by virtue of being reactive with a different epitope of the RSV F protein antigen than the subject antibody of the invention.
- the present invention provides a method for passive immunotherapy of RSV disease in a human by administering to said human an effective amount of the pharmaceutical composition of the invention for the prophylactic or therapeutic treatment of RSV infection.
- the present invention provides methods for, and components useful in, the recombinant production of human and altered antibodies (e.g., engineered antibodies, CDRs, Fab or F(ab) 2 fragments, or analogs thereof) which are derived from human neutralizing monoclonal antibodies (mAbs) for the F protein of RSV.
- These components include isolated nucleic acid sequences encoding same, recombinant plasmids containing the nucleic acid sequences under the control of selected regulatory sequences which are capable of directing the expression thereof in host cells (preferably mammalian) transfected with the recombinant plasmids.
- the production method involves culturing a transfected host cell line of the present invention under conditions such that the human or altered antibody is expressed in said cells and isolating the expressed product therefrom.
- a method to diagnose the presence of RSV in a human which comprises contacting a sample of biological fluid with the human antibodies and altered antibodies and fragments thereof of the instant invention and assaying for the occurrence of binding between said human antibody (or altered antibody, or fragment) and RSV.
- Fig. 1A is a graph illustrating the competition of G ⁇ -1 scFV phage binding with RSV19 mAb [International patent publication No. WO92/04381, published March 19, 1992] .
- Fig. IB is a graph illustrating the competition of
- FIG. 2 is a graph illustrating virus neutralization by scFV phages, G ⁇ -1, G ⁇ -3 , and G ⁇ -1 with RSV strain 273.
- Fig. 3 illustrates the DNA sequence [SEQ ID NO : 1] and protein sequence (amino acids reported in single letter code) [SEQ ID NO : 2] for the G ⁇ -1 light chain variable region, processed N-terminus through framework IV.
- Fig. 4 illustrates the DNA sequence [SEQ ID NO : 3] and protein sequence (amino acids reported in single letter code) [SEQ ID NO : 4] for the G ⁇ -1 heavy chain variable region, processed N-terminus through framework IV.
- Fig. 5 illustrates the cloning strategy used for the construction of the G ⁇ -1 monoclonal antibody.
- the heavy chain V region was cloned into the pCD derivative vector as a Xhol - Apal fragment.
- the entire light chain V region was cloned into the pCN derivative vector, 43-lpcn, as a Sacl - Avrll fragment. Details are described below.
- Fig. 6 provides a comparison of the heavy chain amino acid sequences of the G ⁇ -1 single chain F v [SEQ ID NO: 5] and various monoclonal antibodies of this invention.
- the amino acid sequences of the heavy chains for the A [SEQ ID NO : 7] and B [SEQ ID NO: 8] constructs are shown.
- Numbering of the residues is based on the germline (GL) gene Dp58 [SEQ ID NO: 6] , beginning at the mature processed amino terminus and ending at CDR3.
- the "-" indicates identity to the preceding sequence (eg., A compared to B) .
- Bold residues correspond to the leader region, and to CDRs 1-3.
- Fig. 7 provides a comparison of the light chain amino acid sequences of the G ⁇ -IA single chain F v [SEQ ID NO: 9] and various monoclonal antibodies of this invention.
- the amino acid sequences of the light chains for the A [SEQ ID NO: 11] and B [SEQ ID NO: 12] constructs are shown. Numbering of the residues in the
- VK region is based on the germline (GL) gene DpL8 [SEQ ID NO: 10] , beginning at the mature processed amino terminus and ending at CDR3.
- GL germline
- DpL8 SEQ ID NO: 10
- the actual numbering is also shown for G ⁇ -IA.
- the "-" indicates identity to the preceding sequence .
- Figs. 8A to 8F illustrate the continuous DNA sequence [SEQ ID NO: 13] of the expression plasmid G ⁇ - lApcd containing the RSV neutralizing human G ⁇ -1 mAb for the heavy chain. The start of translation, leader peptide, amino-terminal processing site, carboxy terminus of the G ⁇ -1 heavy chain, and Eco RI restriction endonuclease cleavage site are shown.
- Figs. 9A to 9E illustrate the continuous DNA sequence [SEQ ID NO: 14] of the expression plasmid G ⁇ - lApcn containing the RSV neutralizing human G ⁇ -1 mAb for the light chain.
- the corresponding features for the light chain as for Figs. 8A-8F are shown.
- Figs. 10A and 10B illustrate the continuous DNA sequence [SEQ ID NO: 15] of the coding region of the heavy chain of plasmid G ⁇ -lBpcd.
- Bolded residues indicate differences from the full vector sequence for G ⁇ -lApcd in Figs. 8A-8F [SEQ ID NO: 13].
- Fig. 11 is the DNA sequence [SEQ ID NO: 16] of the coding region for the light chain of plasmid G ⁇ -lBpcn.
- Bolded residues indicate differences from the full vector sequence for G ⁇ -lApcn in Figs. 9A-9E [SEQ ID NO:
- This invention provides useful human monoclonal antibodies (and fragments thereof) reactive with the F protein of RSV, isolated nucleic acids encoding same and various means for their recombinant production as well as therapeutic, prophylactic and diagnostic uses of such antibodies and fragments thereof.
- altered antibody refers to a protein encoded by an altered immunoglobulin coding region, which may be obtained by expression in a selected host cell.
- altered antibodies are engineered antibodies (e.g., chimeric, humanized, or reshaped or immunologically edited human antibodies) or fragments thereof lacking all or part of an immunoglobulin constant region, e.g., Fv, Fab, or F(ab') 2 and the like.
- altered immunoglobulin coding region refers to a nucleic acid sequence encoding an altered antibody of the invention or a fragment thereof.
- Reshaped human antibody refers to an altered antibody in which minimally at least one CDR from a first human monoclonal donor antibody is substituted for a CDR in a second human acceptor antibody. Preferrably all six CDRs are replaced. More preferrably an entire antigen combining region (e.g., Fv, Fab or F(ab') 2 ) from a first human donor monoclonal antibody is substituted for the corresponding region in a second human acceptor monoclonal antibody. Most preferrably the Fab region from a first human donor is operatively linked to the appropriate constant regions of a second human acceptor antibody to form a full length monoclonal antibody.
- an entire antigen combining region e.g., Fv, Fab or F(ab') 2
- First immunoglobulin partner refers to a nucleic acid sequence encoding a human framework or human immunoglobulin variable region in which the native (or naturally-occurring) CDR-encoding regions are replaced by the CDR-encoding regions of a donor human antibody.
- the human variable region can be an immunoglobulin heavy chain, a light chain (or both chains), an analog or functional fragments thereof.
- Such CDR regions, located within the variable region of antibodies (immunoglobulins) can be determined by known methods in the art. For example, Rabat et al . (Sequences of Proteins of Immunological Interest, 4th Ed., U.S. Department of Health and Human Services, National Institutes of Health (1987)) disclose rules for locating CDRs. In addition, computer programs are known which are useful for identifying CDR regions/structures.
- “Second fusion partner” refers to another nucleotide sequence encoding a protein or peptide to which the first immunoglobulin partner is fused in frame or by means of an optional conventional linker sequence (i.e., operatively linked).
- the fusion partner is an immunoglobulin gene and when so, it is referred to as a "second immunoglobulin partner".
- the second immunoglobulin partner may include a nucleic acid sequence encoding the entire constant region for the same (i.e., homologous - the first and second altered antibodies are derived from the same source) or an additional (i.e., heterologous) antibody of interest.
- the second immunoglobulin partner may be an immunoglobulin heavy chain or light chain (or both chains as part of a single polypeptide) .
- the second immunoglobulin partner is not limited to a particular immunoglobulin class or isotype.
- the second immunoglobulin partner may comprise part of an immunoglobulin constant region, such as found in a Fab, or F(ab) 2 (i.e., a discrete part of an appropriate human constant region or framework region) .
- a second fusion partner may also comprise a sequence encoding an integral membrane protein exposed on the outer surface of a host cell, e.g., as part of a phage display library, or a sequence encoding a protein for analytical or diagnostic detection, e.g., horseradish peroxidase (HRP) , ⁇ -galactosidase, etc.
- HRP horseradish peroxidase
- ⁇ -galactosidase etc.
- Fv, Fc, Fd, Fab, or F(ab') 2 are used with their standard meanings [see, e.g., Harlow et al . , Antibodies A Laboratory Manual, Cold Spring Harbor Laboratory, (1988) ] .
- an “engineered antibody” describes a type of altered antibody, i.e., a full-length synthetic antibody (e.g., a chimeric, humanized, reshaped or immunologically edited human antibody as opposed to an antibody fragment) in which a portion of the light and/or heavy chain variable domains of a selected acceptor antibody are replaced by analogous parts from one or more donor antibodies which have specificity for the selected epitope.
- a full-length synthetic antibody e.g., a chimeric, humanized, reshaped or immunologically edited human antibody as opposed to an antibody fragment
- a portion of the light and/or heavy chain variable domains of a selected acceptor antibody are replaced by analogous parts from one or more donor antibodies which have specificity for the selected epitope.
- such molecules may include antibodies characterized by a humanized heavy chain associated with an unmodified light chain (or chimeric light chain), or vice versa.
- Engineered antibodies may also be characterized by alteration of the nucleic acid sequences encoding the acceptor antibody light and/or heavy variable domain framework regions in order to retain donor antibody binding specificity. These antibodies can comprise replacement of one or more CDRs (preferably all) from the acceptor antibody with CDRs from a donor antibody described herein.
- a “chimeric antibody” refers to a type of engineered antibody which contains naturally-occurring variable region (light chain and heavy chains) derived from a donor antibody in association with light and heavy chain constant regions derived from an acceptor antibody from a heterologous species .
- a “humanized antibody” refers to a type of engineered antibody having its CDRs derived from a non- human donor immunoglobulin, the remaining immunoglobulin-derived parts of the molecule being derived from one (or more) human immunoglobulin (s) .
- framework support residues may be altered to preserve binding affinity [see, e.g., Queen et al . , Proc. Nat'l. Acad. Sci. USA, 86 : 10029-10032 (1989), Hodgson et al . , Bio/Technology, 9:421 (1991)].
- immunologically edited antibody refers to a type of engineered antibody in which changes are made in donor and/or acceptor sequences to edit regions in respect of cloning artifacts, germ line enhancements, etc. aimed at reducing the likelihood of an immunological response to the antibody on the part of a patient being treated with the edited antibody.
- donor antibody refers to an antibody (monoclonal, or recombinant) which contributes the nucleic acid sequences of its variable regions, CDRs, or other functional fragments or analogs thereof to a first immunoglobulin partner, so as to provide the altered immunoglobulin coding region and resulting expressed altered antibody with the antigenic specificity and neutralizing activity characteristic of the donor antibody.
- One donor antibody suitable for use in this invention is a Fab fragment of a human neutralizing monoclonal antibody designated as Fab G ⁇ -1.
- Fab G ⁇ -1 is defined as a having the variable light and heavy chain DNA and amino acid sequences G ⁇ -1 as shown in Figs. 3, 4, 8A-8F and 9A-9E [SEQ ID NOS: 1-4, 13 and 14].
- acceptor antibody refers to an antibody (monoclonal or recombinant) from a source genetically unrelated to the donor antibody, which contributes all (or any portion, but preferably all) of the nucleic acid sequences encoding its heavy and/or light chain framework regions and/or its heavy and/or light chain constant regions to the first immunoglobulin partner.
- a human antibody is the acceptor antibody.
- CDRs are defined as the complementarity determining region amino acid sequences of an antibody which are the hypervariable regions of immunoglobulin heavy and light chains [see, e.g., Rabat et al . , Sequences of Proteins of Immunological Interest, 4th Ed., U.S.
- CDRs refers to all three heavy chain CDRs, or all three light chain CDRs (or both all heavy and all light chain CDRs, if appropriate) .
- CDRs provide the majority of contact residues for the binding of the antibody to the antigen or epitope.
- CDRs of interest in this invention are derived from donor antibody variable heavy and light chain sequences, and include analogs of the naturally occurring CDRs, which analogs also share or retain the same antigen binding specificity and/or neutralizing ability as the donor antibody from which they were derived.
- Fab G ⁇ -1 may be characterized by a certain level of antigen affinity
- a CDR encoded by a nucleic acid sequence of Fab G ⁇ -1 in an appropriate structural environment may have a lower, or higher affinity. It is expected that CDRs of Fab G ⁇ -1 in such environments will nevertheless recognize the same epitope (s) as does the intact Fab G ⁇ -1.
- a "functional fragment” is a partial heavy or light chain variable sequence (e.g., minor deletions at the amino or carboxy terminus of the immunoglobulin variable region) which retains the same antigen binding specificity and/or neutralizing ability as the antibody from which the fragment was derived.
- an “analog” is an amino acid sequence modified by at least one amino acid, wherein said modification can be a chemical modification, or a substitution or a rearrangement of a few amino acids (i.e., no more than 10), which modification permits the amino acid sequence to retain the biological characteristics, e.g., antigen specificity and high affinity, of the unmodified sequence.
- (silent) mutations can be constructed, via substitutions, when certain endonuclease restriction sites are created within or surrounding CDR-encoding regions .
- Analogs may also arise as allelic variations.
- An "allelic variation or modification” is an alteration in the nucleic acid sequence encoding the amino acid or peptide sequences of the invention. Such variations or modifications may be due to degeneracy in the genetic code or may be deliberately engineered to provide desired characteristics. These variations or modifications may or may not result in alterations in any encoded amino acid sequence.
- effector agents refers to non-protein carrier molecules to which the altered antibodies, and/or natural or synthetic light or heavy chains of the donor antibody or other fragments of the donor antibody may be associated by conventional means .
- non-protein carriers can include conventional carriers used in the diagnostic field, e.g., polystyrene or other plastic beads, polysaccharides , e.g., as used in the BIAcore (Pharmacia) system, or other non-protein substances useful in the medical field and safe for administration to humans and animals.
- Other effector agents may include a macrocycle, for chelating a heavy metal atom, or radioisotopes .
- Such effector agents may also be useful to increase the half-life of the altered antibodies, e.g., polyethylene glycol . II . Combina torial Cloning.
- Combinatorial cloning is disclosed generally in PCT Publication No. WO90/14430. Simply stated, the goal of combinatorial cloning is to transfer to a population of bacterial cells the immunological genetic capacity of a human cell, tissue or organ. It is preferred to employ cells, tissues or organs which are immunocompetent . Particularly useful sources include, without limitation, spleen, thymus, lymph nodes, bone marrow, tonsil and peripheral blood lymphocytes. The cells may be optionally RSV stimulated in vi tro, or selected from donors which are known to have produced an immune response or donors who are HIV + but asymptomatic .
- the genetic information isolated from the donor cells can be in the form of DNA or RNA and is conveniently amplified by Polymerase Chain Reaction (PCR) or similar techniques.
- PCR Polymerase Chain Reaction
- the genetic information is preferably converted into cDNA by reverse transcription prior to amplification.
- the amplification can be generalized or more specifically tailored. For example, by a careful selection of PCR primer sequences, selective amplification of immunoglobulin genes or subsets within that class of genes can be achieved.
- the light and heavy chain genes are associated in random combinations to form a random combinatorial library.
- Various recombinant DNA vector systems have been described to facilitate combinatorial cloning [see: PCT Publication No. WO90/14430 supra ; Scott and Smith, Science 249:386- 406 (1990); or U. S. Patent 5,223,409]. Having generated the combinatorial library, the products can, after expression, be conveniently screened by biopanning with RSV F protein or, if necessary, by epitope blocked biopanning as described in more detail below.
- Fab fragments of mAbs can also be used for cloning and screening.
- the present invention contemplates the use of scFv, Fab, or F(ab') 2 fragments to derived full-length mAbs directed against the F protein of RSV.
- these fragments may be independently useful as protective and therapeutic agents in vivo against RSV-mediated conditions or in vi tro as part of an RSV diagnostic, they are employed herein as a component of a reshaped human antibody.
- a scFv fragment contains the light and heavy chain variable regions joined by a linker of about 12 amino acids in either a light-linker-heavy or a heavy-linker-light orientation.
- a Fab fragment contains the entire light chain and amino terminal portion of the heavy chain; and a F(ab') 2 fragment is the fragment formed by two Fab fragments bound by additional disulfide bonds.
- RSV binding monoclonal antibodies provide sources of scFv or Fab fragments which can be obtained from a combinatorial phage library [see, e.g., Winter et al . , Ann. Rev. Immunol., 12:433-455 (1994) or Barbas et al . , Proc. Nat'l. Acad. Sci. (USA) 89, 10164- 10168 (1992), which are both hereby incorporated by reference in their entireties] .
- the Fab G ⁇ -1 or other antibodies described herein may contribute sequences, such as variable heavy and/or light chain peptide sequences, framework sequences, CDR sequences, functional fragments, and analogs thereof, and the nucleic acid sequences encoding them, useful in designing and obtaining various altered antibodies which are characterized by the antigen binding specificity of the donor antibody.
- the present invention thus provides variable light chain and variable heavy chain sequences from the RSV human Fab G ⁇ -IA and sequences derived therefrom.
- the heavy chain variable region of Fab G ⁇ -IA is illustrated by Figs. 4, 8A-8F and 10A-10B [SEQ ID NOS: 3-4, 13 and 15] .
- nucleic acid sequences of this invention, or fragments thereof, encoding the variable light chain and heavy chain peptide sequences are also useful for mutagenic introduction of specific changes within the nucleic acid sequences encoding the CDRs or framework regions, and for incorporation of the resulting modified or fusion nucleic acid sequence into a plasmid for expression.
- silent substitutions in the nucleotide sequence of the framework and CDR-encoding regions can be used to create restriction enzyme sites which would facilitate insertion of mutagenized CDR (and/or framework) regions.
- These CDR-encoding regions may be used in the construction of reshaped human antibodies of this invention.
- variable heavy and light chain amino acid sequences may be constructed which encode the variable heavy and light chain amino acid sequences, and CDR sequences of the invention as well as functional fragments and analogs thereof which share the antigen specificity of the donor antibody.
- the isolated nucleic acid sequences of this invention, or fragments thereof, encoding the variable chain peptide sequences or CDRs can be used to produce altered antibodies, e.g., chimeric or humanized antibodies, or other engineered antibodies of this invention when operatively combined with a second immunoglobulin partner.
- nucleic acid sequences encoding portions of the altered antibody and antibodies described herein
- other such nucleic acid sequences are encompassed by the present invention, such as those complementary to the native CDR-encoding sequences or complementary to the human framework regions surrounding the CDR-encoding regions .
- Such sequences include all nucleic acid sequences which by virtue of the redundancy of the genetic code are capable of encoding the same amino acid sequence as given in Figs. 3 and 4 [SEQ ID NOS: 2 and 4] .
- Figs. 6 and 7 [SEQ ID NOS: 5-12] provide representations of such sequences .
- Other useful DNA sequences encompassed by this invention include those sequences which hybridize under stringent hybridization conditions [See: T.
- hybridizing DNA sequences are at least about 18 nucleotides in length, i.e., about the size of a CDR.
- Altered immunoglobulin coding regions encode altered antibodies which include engineered antibodies such as chimeric antibodies, humanized, reshaped, and immunologically edited human antibodies.
- a desired altered immunoglobulin coding region contains CDR- encoding regions in the form of scFv regions that encode peptides having the antigen specificity of an RSV antibody, preferably a high affinity antibody such as provided by the present invention, inserted into an acceptor immunoglobulin partner.
- the acceptor when the acceptor is an immunoglobulin partner, as defined above, it includes a sequence encoding a second antibody region of interest, for example, an Fc region.
- Immunoglobulin partners may also include sequences encoding another immunoglobulin to which the light or heavy chain constant region is fused in frame or by means of a linker sequence.
- Engineered antibodies directed against functional fragments or analogs of RSV may be designed to elicit enhanced binding with the same antibody.
- the immunoglobulin partner may also be associated with effector agents as defined above, including non- protein carrier molecules, to which the immunoglobulin partner may be operatively linked by conventional means .
- Fusion or linkage between the immunoglobulin partners, e.g., antibody sequences, and the effector agent may be by any suitable means, e.g., by conventional covalent or ionic bonds, protein fusions, or hetero-bifunctional cross-linkers, e.g., carbodiimide, glutaraldehyde, and the like.
- suitable means e.g., by conventional covalent or ionic bonds, protein fusions, or hetero-bifunctional cross-linkers, e.g., carbodiimide, glutaraldehyde, and the like.
- linker sequences which simply provide for a desired amount of space between the second immunoglobulin partner and the effector agent may also be constructed into the altered immunoglobulin coding region.
- the design of such linkers is well known to those of skill in the art.
- signal sequences for the molecules of the invention may be modified to enhance expression.
- the reshaped human antibody having the signal sequence and CDRs derived from the Fab G ⁇ -1 heavy chain sequence may have the original signal peptide replaced with another signal sequence such as the Campath leader sequence [Page, M. J. et al . , BioTechnology 9:64-68(1991)].
- An exemplary altered antibody, a reshaped human antibody contains a variable heavy and the entire light chain peptide or protein sequence having the antigen specificity of Fab G ⁇ -1, fused to the constant heavy regions C _ ⁇ -C H - 3 derived from a second human antibody.
- the engineered antibody of the invention may have attached to it an additional agent.
- the procedure of recombinant DNA technology may be used to produce an engineered antibody of the invention in which the Fc fragment or C H - 2 C H - 3 domain of a complete antibody molecule has been replaced by an enzyme or other detectable molecule (i.e., a polypeptide effector or reporter molecule) .
- Another desirable protein of this invention may comprise a complete antibody molecule, having full length heavy and light chains, or any discrete fragment thereof, such as the Fab or F(ab') 2 fragments, a heavy chain dimer, or any minimal recombinant fragments thereof such as an F v or a single-chain antibody (SCA) or any other molecule with the same specificity as the selected donor Fab G ⁇ -1.
- Such protein may be used in the form of an altered antibody, or may be used in its unfused form.
- immunoglobulin partner is derived from an antibody different from the donor antibody, e.g., any isotype or class of immunoglobulin framework or constant regions
- Engineered antibodies can comprise immunoglobulin (Ig) constant regions and variable framework regions from one source, e.g., the acceptor antibody, and one or more (preferably all) CDRs from the donor antibody, e.g., the anti-RSV antibody described herein.
- alterations e.g., deletions, substitutions, or additions, of the acceptor mAb light and/or heavy variable domain framework region at the nucleic acid or amino acid levels, or the donor CDR regions may be made in order to retain donor antibody antigen binding specificity or to reduce potential immunogenicity .
- Such engineered antibodies are designed to employ one (or both) of the variable heavy and/or light chains of the RSV mAb (optionally modified as described) or one or more of the below-identified heavy or light chain CDRs .
- the engineered antibodies of the invention are neutralizing, i.e., they desirably inhibit virus growth in vi tro and in vivo in animal models of RSV infection.
- Such engineered antibodies may include a reshaped human antibody containing the human heavy and light chain constant regions fused to the RSV antibody functional fragments.
- a suitable human (or other animal) acceptor antibody may be one selected from a conventional database, e.g., the RABAT ® database, Los Alamos database, and Swiss Protein database, by homology to the nucleotide and amino acid sequences of the donor antibody.
- a human antibody characterized by a homology to the framework regions of the donor antibody (on an amino acid basis) may be suitable to provide a heavy chain constant region and/or a heavy chain variable framework region for insertion of the donor CDRs.
- a suitable acceptor antibody capable of donating light chain constant or variable framework regions may be selected in a similar manner. It should be noted that the acceptor antibody heavy and light chains are not required to originate from the same acceptor antibody.
- heterologous framework and constant regions are selected from human immunoglobulin classes and isotypes, such as IgG (subtypes 1 through 4), IgM, IgA and IgE.
- the Fc domains are not limited to native sequences, but include mutant variants known in the art that alter function. For example, mutations have been described in the Fc domains of certain IgG antibodies that reduce Fc-mediated complement and Fc receptor binding [see, e.g., A. R. Duncan et al . , Nature,
- a gene may be constructed in which a DNA sequence encoding part of a human immunoglobulin chain is fused to a DNA sequence encoding a non-immunoglobulin amino acid sequence such as a polypeptide effector or reporter molecule.
- the altered antibody thus preferably has the structure of a natural human antibody or a fragment thereof, and possesses the combination of properties required for effective therapeutic use, e.g., treatment of RSV mediated diseases in man, or for diagnostic uses.
- variable domain amino acids may be further modified by changes in variable domain amino acids without necessarily affecting the specificity and high affinity of the donor antibody (i.e., an analog) . It is anticipated that heavy and light chain amino acids may be substituted by other amino acids either in the variable domain frameworks or CDRs or both.
- variable or constant region may be altered to enhance or decrease selective properties of the molecules of the instant invention, as described above.
- dimerization binding to Fc receptors, or the ability to bind and activate complement [see, e.g., Angal et al . , Mol. Immunol, 30:105-108 (1993); Xu et al . , J. Biol. Chem, 269:3469- 3474 (1994); and Winter et al . , EP 307,434-B].
- Such antibodies are useful in the prevention and treatment of RSV mediated disorders, as discussed below.
- the resulting reshaped human antibodies of this invention can be expressed in recombinant host cells, e.g., COS, CHO or myeloma cells.
- a conventional expression vector or recombinant plasmid is produced by placing these coding sequences for the altered antibody in operative association with conventional regulatory control sequences capable of controlling the replication and expression in, and/or secretion from, a host cell.
- Regulatory sequences include promoter sequences, e.g., CMV promoter, and signal sequences, which can be derived from other known antibodies.
- a second expression vector can be produced having a DNA sequence which encodes a complementary antibody light or heavy chain.
- this second expression vector is identical to the first except insofar as the coding sequences and selectable markers are concerned. This ensures as far as possible that each polypeptide chain is functionally expressed.
- the heavy and light chain coding sequences for the altered antibody may reside on a single vector.
- a selected host cell is co-transfected by conventional techniques with both the first and second vectors (or simply transfected by a single vector) to create the transfected host cell of the invention comprising both the recombinant or synthetic light and heavy chains.
- the transfected cell is then cultured by conventional techniques to produce the engineered antibody of the invention.
- the production of the antibody which includes the association of both the recombinant heavy chain and light chain is measured in the culture by an appropriate assay, such as an enzyme- linked immunosorbent assay (ELISA) or radioimmunoassay (RIA) .
- ELISA enzyme- linked immunosorbent assay
- RIA radioimmunoassay
- Suitable vectors for the cloning and subcloning steps employed in the methods and construction of the compositions of this invention may be selected by one of skill in the art.
- the conventional pUC series of cloning vectors may be used.
- One vector used is pUC19, which is commercially available from supply houses, such as Amersham (Buckinghamshire, United Kingdom) or Pharmacia (Uppsala, Sweden) .
- Any vector, which is capable of replicating readily, has an abundance of cloning sites and selectable genes (e.g., antibiotic resistance) , and is easily manipulated, may be used for cloning.
- the selection of the cloning vector is not a limiting factor in this invention.
- the vectors employed for expression of the engineered antibodies according to this invention may be selected by one of skill in the art from any conventional vectors .
- Preferred vectors include for example plasmids pCD or pCN.
- the vectors also contain selected regulatory sequences (such as CMV promoters) which direct the replication and expression of heterologous DNA sequences in selected host cells .
- These vectors contain the above described DNA sequences which code for the engineered antibody or altered immunoglobulin coding region.
- the vectors may incorporate the selected immunoglobulin sequences modified by the insertion of desirable restriction sites for ready manipulation.
- the expression vectors may also be characterized by genes suitable for amplifying expression of the heterologous DNA sequences, e.g., the mammalian dihydrofolate reductase gene (DHFR) .
- DHFR mammalian dihydrofolate reductase gene
- Other preferable vector sequences include a polyadenylation (polyA) signal sequence, such as from bovine growth hormone
- BGH betaglobin promoter sequence
- betaglopro betaglobin promoter sequence
- the expression vectors useful herein may be synthesized by techniques well known to those skilled in this art.
- the components of such vectors e.g. replicons, selection genes, enhancers, promoters, signal sequences and the like, may be obtained from commercial or natural sources or synthesized by known procedures for use in directing the expression and/or secretion of the product of the recombinant DNA in a selected host.
- Other appropriate expression vectors of which numerous types are known in the art for mammalian, bacterial, insect, yeast, and fungal expression may also be selected for this purpose.
- the present invention also encompasses a cell line transfected with a recombinant plasmid containing the coding sequences of the engineered antibodies or altered immunoglobulin molecules thereof.
- Host cells useful for the cloning and other manipulations of these cloning vectors are also conventional. However, most desirably, cells from various strains of E. coli are used for replication of the cloning vectors and other steps in the construction of altered antibodies of this invention.
- Suitable host cells or cell lines for the expression of the engineered antibody or altered antibody of the invention are preferably mammalian cells such as CHO, COS, a fibroblast cell (e.g., 3T3), and myeloid cells, and more preferably a CHO or a myeloid cell.
- Human cells may be used, thus enabling the molecule to be modified with human glycosylation patterns.
- other eukaryotic cell lines may be employed.
- the selection of suitable mammalian host cells and methods for transformation, culture, amplification, screening and product production and purification are known in the art. See, e.g., Sambrook et al . , Molecular Cloning (A Laboratory Manual), 2nd edit., Cold Spring Harbor Laboratory (1989) .
- Bacterial cells may prove useful as host cells suitable for the expression of the recombinant scFvs, Fabs and MAbs of the present invention [see, e.g., Pl ⁇ ckthun, A., Immunol. Rev., 130:151-188 (1992)].
- the tendency of proteins expressed in bacterial cells to be in an unfolded or improperly folded form or in a non- glycosylated form does not pose as great a concern because Fabs are not normally glycosylated and can be engineered for exported expression, thereby reducing the high concentration that facilitates misfolding. Nevertheless, any recombinant Fab produced in a bacterial cell would be screened for retention of antigen binding ability.
- bacterial cell If the molecule expressed by the bacterial cell was produced and exported in a properly folded form, that bacterial cell would be a desirable host.
- E. coli used for expression are well-known as host cells in the field of biotechnology.
- Various strains of B . subtiiis, Streptomyces , other bacilli and the like may also be employed in this method.
- strains of yeast cells known to those skilled in the art are also available as host cells, as well as insect cells, e.g. Drosophila and Lepidoptera and viral expression systems [see, e.g. Miller et al . , Genetic Engineering, 8:277-298, Plenum Press (1986) and references cited therein] .
- the transfection methods required to produce the host cells of the invention, and culture methods necessary to produce the altered antibody of the invention from such host cell are all conventional techniques.
- the altered antibodies of the invention may be purified from the cell culture contents according to standard procedures of the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis and the like. Such techniques are within the skill of the art and do not limit this invention.
- Yet another method of expression of reshaped antibodies may utilize expression in a transgenic animal.
- An exemplary systems is described in U. S. Patent No. 4,873,316.
- the expression system described in that reference uses the animal's casein promoter and, when transgenically incorporated into a mammal, permits the female to produce the desired recombinant protein in its milk.
- the engineered antibody is then examined for in vi tro activity by use of an appropriate assay.
- conventional ELISA assay formats are employed to assess qualitative and quantitative binding of the altered antibody to RSV.
- other in vi tro assays and in vivo animal models may also be used to verify neutralizing efficacy prior to subsequent human clinical studies performed to evaluate the persistence of the altered antibody in the body despite the usual clearance mechanisms .
- This invention also relates to a method of treating humans experiencing RSV-related symptoms which comprises administering an effective dose of antibodies including one or more of the antibodies (altered, reshaped, monoclonal, etc.) described herein or fragments thereof.
- the therapeutic response induced by the use of the molecules of this invention is produced by binding to RSV and thus subsequently blocking RSV propagation.
- the molecules of the present invention when in preparations and formulations appropriate for therapeutic use, are highly desirable for those persons experiencing RSV infection. For example, longer treatments may be desirable when treating seasonal episodes or the like.
- the dose and duration of treatment relates to the relative duration of the molecules of the present invention in the human circulation, and can be adjusted by one of skill in the art depending upon the condition being treated and the general health of the patient.
- the altered antibodies, antibodies and fragments thereof of this invention may also be used alone or in conjunction with other antibodies, particularly human or humanized mAbs reactive with other epitopes on the F protein or other RSV target antigens as prophylactic agents .
- the mode of administration of the therapeutic and prophylactic agents of the invention may be any suitable route which delivers the agent to the host.
- the altered antibodies, antibodies, engineered antibodies, and fragments thereof, and pharmaceutical compositions of the invention are particularly useful for parenteral administration, i.e., subcutaneously, intramuscularly, intravenously, or intranasally .
- Therapeutic and prophylactic agents of the invention may be prepared as pharmaceutical compositions containing an effective amount of the altered antibody of the invention as an active ingredient in a pharmaceutically acceptable carrier.
- An aqueous suspension or solution containing the antibody, preferably buffered at physiological pH, in a form ready for injection is preferred.
- compositions for parenteral administration will commonly comprise a solution of the engineered antibody of the invention or a cocktail thereof dissolved in an pharmaceutically acceptable carrier, preferably an aqueous carrier.
- an aqueous carrier e.g. 0.4% saline, 0.3% glycine, and the like. These solutions are sterile and generally free of particulate matter. These solutions may be sterilized by conventional, well known sterilization techniques (e.g., filtration).
- the compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, etc.
- the concentration of the antibody of the invention in such pharmaceutical formulation can vary widely, i.e., from less than about 0.5%, usually at or at least about 1% to as much as 15 or 20% by weight and will be selected primarily based on fluid volumes, viscosities, etc., according to the particular mode of administration selected.
- a pharmaceutical composition of the invention for intramuscular injection could be prepared to contain 1 mL sterile buffered water, and between about 1 ng to about 100 mg, e.g. about 50 ng to about 80 mg, or more preferably, about 5 mg to about 75 mg, of an engineered antibody of the invention.
- a pharmaceutical composition of the invention for intravenous infusion could be made up to contain about 250 ml of sterile Ringer's solution, and about 1 to about 75 and preferably 5 to about 50 mg/ml of an engineered antibody of the invention.
- Actual methods for preparing parenterally administrable compositions are well known or will be apparent to those skilled in the art and are described in more detail in, for example, Remington's Pharmaceutical Science, 15th ed., Mack Publishing Company, Easton, Pennsylvania.
- the therapeutic and prophylactic agents of the invention when in a pharmaceutical preparation, be present in unit dose forms.
- the appropriate therapeutically effective dose can be determined readily by those of skill in the art.
- one dose of approximately 0.1 mg to approximately 20 mg per 70 kg body weight of a protein or an antibody of this invention should be administered parenterally, preferably i.v. or i.m. (intramuscularly) .
- Such dose may, if necessary, be repeated at appropriate time intervals selected as appropriate by a physician.
- the altered antibodies and engineered antibodies of this invention may also be used in diagnostic regimens, such as for the determination of RSV mediated disorders or tracking progress of treatment of such disorders.
- diagnostic regimens such as for the determination of RSV mediated disorders or tracking progress of treatment of such disorders.
- these altered antibodies may be conventionally labeled for use in ELISAs and other conventional assay formats for the measurement of RSV levels in serum, plasma or other appropriate tissue, or the release by human cells in culture.
- the nature of the assay in which the altered antibodies are used are conventional and do not limit this disclosure.
- the antibodies, altered antibodies or fragments thereof described herein can be lyophilized for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective with conventional immunoglobulins and art-known lyophilization and reconstitution techniques can be employed.
- Single chain (sc) Fv libraries were prepared from an individual purposely exposed to RSV and selected against recombinant RSV F-protein following described procedures [R. H. Jackson et al , in Protein Engineering, A Practical Approach , A. R. Rees et al eds, Oxford University Press, chapter 12, pp. 277-301, 1992; H. R. Hoogenboo et al . , Nucl . Acid Res . , 19: 4133-4137 (1991); J. D. Marks et al . , J. Mol. Biol. , 222: 581-597 (1991)] . Briefly, lymphocytes were isolated from a blood sample taken 15 days post exposure.
- RNA isolated from the lymphocytes was used for preparation of scFv encoding repertoires for phage display.
- Sets of V- region primers were paired with constant region primers for heavy chain domain 1 IgG and IgM and light chain C- ⁇ and C- ⁇ and then linked in a scFv VH-VL orientation with a 15 amino acid spacer (glycine 4 -serine) 3 [SEQ ID NO: 21] by overlap PCR [see J. D. Marks et al . , cited above, for description of the primers] .
- the resulting four scFv repertoires (V- ⁇ with IgG and IgM, V- ⁇ with IgG and IgM) were cloned into a phagemid vector similar to pHENl [H. R. Hoogenboom et al . , cited above] resulting in fusion of the scFvs to gene III of phage fd.
- the vector was then transformed into E. coli (e.g., strain TGI) by electroporation to yield the corresponding phagemid libraries.
- MarvalTM non-fat dry milk were incubated for 90 minutes in a tube coated with
- E. coli were infected with the eluted phage and 96 colonies from each starting library were superinfected with helper phage and screened for F-protein binding activity. Only four positive clones were obtained from the 2 IgM libraries, whereas 41 positives were observed for the IgG libraries. By partial sequence analysis, all of the clones carried one of three different heavy chains . Complete sequences were obtained for the heavy and light chain V-regions for six clones, all from the IgG libraries.
- G ⁇ -1 Three clones: G ⁇ -1, G ⁇ -3 (lysate binding positive) , and G ⁇ -1 (lysate binding negative) , where "K” and " ⁇ ” designate the class of the light chain, were characterized further for competition of their binding by F-protein specific neutralizing monoclonal antibodies, and their ability to inhibit virus infection.
- G ⁇ -1 was strongly inhibited by both antibodies.
- G ⁇ -1 was significantly inhibited by B4 only.
- G ⁇ -3 was not inhibited by either antibody (shown for G ⁇ -1 only; see Figs.
- a phage preparation of the non- neutralizing Fab 5-16 was tested in the same assay. In three out of four assays, this preparation also showed good neutralization activity, as did the control phage in two of these assays (Table I, experiments 4-7) . This confounding observation of variable neutralization by both Fab 5-16 and control M13K07 phage rendered the viral neutralization studies inconclusive.
- Virus at 100 infectious centers/well was incubated with dilutions of the indicated phage for 1 hr and then added to susceptible cells for 3 hr. The virus /phage solution was aspirated and replaced with fresh medium and the cells were incubated overnight before peroxidase staining for virus infected cells.
- aru ampicillin resistance units, a measure of phagmid containing particles.
- kru kanamycin resistance units, a measure of particles containing the phage genome (for the M13K07 control only) .
- G ⁇ -1 was selected as the most likely candidate for a potent neutralizing antibody based on (1) its apparent better binding to F-protein, (2) its selective inhibition of binding by the B4 antibody, and (3) its suggested activity over background in the virus neutralization assay.
- Figs. 3 [SEQ ID NOS: 1 and 2] and 4 [SEQ ID NOS: 3 and 4], respectively.
- the heavy chain variable region and the light chain variable region from the G ⁇ -1 plasmid were cloned into derivatives of plasmid pCDN [Nambi, A. et al . , Mol. Cell. Biochem. , 131:75-86 (1994)] in which the expression of the antibody chain is driven by the cytomegalovirus promoter (CMV) promoter.
- CMV cytomegalovirus promoter
- Plasmid pCD-HC68B is used for expressing full length heavy chains and plasmid pCN-HuLC, for expressing full length light chains.
- the heavy chain of G ⁇ -1 was PCR amplified from G ⁇ -1 phagemid DNA, using primers for the amino terminus and framework 4 of the variable region.
- the resulting PCR fragment was cut with Xhol (site introduced by the amino terminus primer) and BstEII (naturally occurring site in framework 4), and cloned into an intermediate vector, F4HCV, at the XhoI/BstEII sites.
- This cloning grafted the variable region of G ⁇ -1 onto the constant region of another anti-RSV heavy chain 194-F4 [cloned at SmithKline Beecham from a human hybridoma] .
- This intermediate clone was cut with Xhol and Bspl20I, and introduced into the same sites in pCD- HC68B.
- the Xhol site is introduced at the amino terminus by the PCR primer and, when cloned into pCD- HC68B at the same site is preceded in frame by the Campath leader sequence.
- the Bspl20I site is a naturally occurring, highly conserved sequence at the beginning of the C H - ⁇ domain, and when cloned into pCD- HC68B at the same site, is in frame with the remaining sequence for the C H - ⁇ through C H - 3 regions of human IgGi .
- G ⁇ -lApcd Figs. 8A-8F [SEQ ID NO: 13]
- the amino acids immediately following the Campath leader are EVQLLE [SEQ ID NO: 17], where the residues LE are encoded by the nucleotide sequence for the Xhol cloning site.
- the light chain of G ⁇ -1 was PCR amplified from the G ⁇ -1 phagemid DNA, using primers for the amino terminus and framework 4 of the variable region.
- the resulting PCR fragment was cut with Sacl (site introduced by the amino terminus primer) and Avrll (naturally occurring site in framework 4), and cloned into 43-lpcn at the Sacl/Avrll sites.
- Sacl site introduced by the amino terminus primer
- Avrll naturally occurring site in framework 4
- nucleotide sequences of the plasmids G ⁇ -lApcd and G ⁇ -lApcn are shown in Figs. 8A-8F [SEQ ID NO: 13] and 9A-9E [SEQ ID NO: 14] respectively.
- This set of vectors was used to produce antibody G ⁇ -IA in COS cells and in CHO cells.
- the final PCR product was digested with restriction enzymes, EcoRI and Bspl20I, and cloned into the G ⁇ -lApcd vector at the same sites to create G ⁇ -lBpcd.
- the final construct was sequenced to verify that the amino terminus of the heavy chain had been corrected from EVQLLE [SEQ ID NO : 17] to EVQLVE [SEQ ID NO : 18] (see Fig 6) .
- the nucleotide sequence of coding region for the corrected heavy chain, G ⁇ -IB is shown in Figs. 10A-10B [SEQ ID NO: 15] .
- the final PCR product was digested with restriction enzymes, EcoRI and Avrll and cloned into the G ⁇ -lApcn vector at the same sites to create G ⁇ -lBpcn.
- the final construct was sequenced to verify that the amino terminus of the light chain had been corrected from --EL to QSVL (amino acids 1-4 of SEQ ID NO: 10) .
- the nucleotide sequence of coding region for the corrected light chain, G ⁇ -IB is shown in Fig. 11 [SEQ ID NO: 16] .
- This vector G ⁇ -lBpcn was used with G ⁇ - IBpcd to produce antibody G ⁇ -IB, in COS cells and in CHO cells .
- Example 4 Production of G ⁇ -1 mABs in Mammalian Cells
- the mAb was prepared from the day 3 + day 5 conditioned medium by standard protein A affinity chromatography methods (e.g., as described in Protocols in Molecular Biology) using, for example, Prosep A affinity resin (Bioprocessing Ltd., UK).
- G ⁇ -IB mAB 100- 200 mgs
- the vectors were introduced into a proprietary CHO cell system.
- dhfr CHO cells as previously described [P. Hensley et al . , J. Biol. Chem. , 269:23949-23958 (1994)].
- a total of 30 ⁇ g of linearized plasmid DNA (15 ⁇ g each of the A or B set of heavy chain and light chain vectors) is electroporated into lxlO 7 cells.
- the cells are initially selected in nucleoside- free medium in 96 well plates. After three to four weeks, media from growth positive wells is screened for human immunoglobulin using an ELISA assay. The highest expressing colonies are expanded and selected in increasing concentrations of methotrexate for amplification of the transfected vectors.
- the antibody is purified from conditioned medium by standard procedures using protein A affinity chromatography (Protein A sepharose, Pharmacia) followed by size exclusion chromatography (Superdex 200, Pharmacia) .
- the concentration and the antigen binding activity of the eluted antibody are measured by ELISA.
- the antibody containing fractions are pooled and further purified by size exclusion chromatography.
- SDS-PAGE the predominant protein product migrated at approximately 150 kd under non-reducing conditions and as two bands of 50 and 25 kd under reducing conditions .
- the purity was > 90%, as judged by SDS-PAGE, and the concentration was accurately determined by amino acid analysis.
- Example 5 Binding of the G ⁇ -1 mABs to recombinant F protein Binding of the G ⁇ -1 mABs to recombinant F protein was measured in a standard solid phase ELISA. Antigen diluted in PBS pH 7.0 was adsorbed onto polystyrene round-bottom microplates (Dynatech, Immunolon II) for 18 hours. Wells were then aspirated and blocked with 0.5% boiled casein (BC) in PBS containing 1% Tween 20
- the antigen binding epitope of the G ⁇ -1 mABs was examined in a competition ELISA.
- the G ⁇ -1 mABs were mixed with increasing concentrations of RSMU19 or B4 , two potent neutralizing mAbs [Tempest et al . , Biotech. , 9: 266-271 (1991); Kennedy et al . , J. Gen. Virol., 69: 3023-3032 (1988)] and added to F protein-coated wells.
- the epitope regions recognized by mAbs RSMU19 and B4 are quite distinct from each other as previously described in Arbiza et al . , J. Gen. Virol. , 73: 2225-2234 (1992).
- the concentration of the G ⁇ -1 mABs used in competition studies was determined previously to give 90% maximal binding to F antigen. Binding of the G ⁇ -1 mABs in the presence of other mABs was detected using HRP-labelled goat anti-human IgG. The reaction was developed as stated above.
- the ability of the G ⁇ -1 mABs to inhibit virus- induced cell fusion was determined using a modification of the in vi tro microneutralization assay [Beeler et al . , J. Virol. , 63:2941-2950 (1989)].
- 50 ⁇ l of RS Long strain virus (10-100 TCID 50 /well [American Type Culture Collection ATCC VR-26] were mixed with 0.1 ml VERO cells (5X10 3 /well) [ATCC CCL-81] in Minimum Essential Media (MEM) containing 2% fetal calf serum
- FCS Fluorescence-Activated Cell Sorting
- Fusion-inhibition titers were defined as the concentration of antibody which caused a 50% reduction in ELISA signal (ED 50 ) as compared to virus controls. Based on the curve generated in the ELISA by the standard virus titration, a 50% reduction in O.D. 450 corresponded to > 90% reduction in virus titer. Calculation of the 50% point was based on regression analysis of the dose titration.
- the G ⁇ -1 mABs demonstrated potent in vi tro fusion- inhibition activity against type A RS Long strain virus (ED 50 for mAB B of 0.51 + 0.38 ⁇ g/ml) .
- ED 50 for mAB B 0.51 + 0.38 ⁇ g/ml
- G ⁇ -1 mAB B was more active than the humanized mAB RSHZ19 (ED 50 of 0.4-3.0 ⁇ g/ml) [Wyde et al . , Pediatr . Res . , 38 (4 ): 543-550 ] in comparative assays .
- Balb/c mice (5/group) were inoculated mtraperitoneally with doses ranging from 0.06 mg/kg to 5 mg/kg of G ⁇ -1 mAB B either 24 hours prior (prophylaxis) or 4 days after (therapy) intranasal infection with 10 5 PFU of the A2 strain of human RSV.
- mice were sacrificed 5 days after infection. Lungs were harvested and homogenized to determine virus titers.
- Virus was undetectable in the lungs of mice treated prophylactically with > 1.25 mg/kg G ⁇ -1 mAB B either prophylactically or therapeutically. See Table II below. Significant viral clearance (2-3 logio) was also achieved in animals receiving 0.31 mg/kg G ⁇ -1 mAB B either prophylactically or therapeutically. Table II: G ⁇ -1 mAB B Prophylaxis and Therapy in Balb/c
- the G ⁇ -1 mABs have potent antiviral activity in vitro against a broad range of native RSV isolates of both type A and B, and show prophylactic and therapeutic efficacy in vivo in animal models.
- the G ⁇ -1 mABs are candidates for therapeutic, prophylactic, and diagnostic application in man.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13470299P | 1999-05-18 | 1999-05-18 | |
US134702P | 1999-05-18 | ||
PCT/US2000/013694 WO2000069462A1 (en) | 1999-05-18 | 2000-05-18 | Human monoclonal antibody |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1178829A1 true EP1178829A1 (de) | 2002-02-13 |
EP1178829A4 EP1178829A4 (de) | 2005-06-08 |
Family
ID=22464579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00939304A Withdrawn EP1178829A4 (de) | 1999-05-18 | 2000-05-18 | Menschlicher monoklonaler antikörper |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1178829A4 (de) |
JP (1) | JP2002543822A (de) |
AR (1) | AR030019A1 (de) |
AU (1) | AU5441000A (de) |
CO (1) | CO5280147A1 (de) |
WO (1) | WO2000069462A1 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9963500B2 (en) | 2015-10-29 | 2018-05-08 | Merck Sharp & Dohme Corp. | Antibody neutralizing human respiratory syncytial virus |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4794301B2 (ja) | 2003-06-11 | 2011-10-19 | 中外製薬株式会社 | 抗体の製造方法 |
TW200530269A (en) | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
WO2006106903A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | sc(Fv)2構造異性体 |
EP1870459B1 (de) | 2005-03-31 | 2016-06-29 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur polypeptidherstellung mit regulation des zusammenbaus |
CN101262885B (zh) | 2005-06-10 | 2015-04-01 | 中外制药株式会社 | 含有sc(Fv)2的药物组合物 |
CN101237890A (zh) | 2005-06-10 | 2008-08-06 | 中外制药株式会社 | 含有葡甲胺的蛋白质制剂的稳定剂及其利用 |
AU2006256030B2 (en) * | 2005-06-10 | 2012-06-21 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical compositions containing sc(Fv)2 |
EP2009101B1 (de) | 2006-03-31 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Antikörpermodifikationsverfahren für die aufreinigung eines bispezifischen antikörpers |
EP1997830A1 (de) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung |
US9193780B2 (en) | 2008-06-05 | 2015-11-24 | Ablynx N.V. | Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases |
CN105061592A (zh) | 2009-06-05 | 2015-11-18 | 埃博灵克斯股份有限公司 | 用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体 |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
EP2507262A1 (de) | 2009-11-30 | 2012-10-10 | Ablynx N.V. | Verbesserte gegen hrsv gerichtete aminosäuresequenzen und polypeptide damit zur prävention und/oder behandlung von atemwegsinfektionen |
TWI659968B (zh) * | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | 針對呼吸道融合病毒f蛋白質的人類抗體及其使用方法 |
US11124576B2 (en) | 2013-09-27 | 2021-09-21 | Chungai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
SG11201803989WA (en) | 2015-12-28 | 2018-06-28 | Chugai Pharmaceutical Co Ltd | Method for promoting efficiency of purification of fc region-containing polypeptide |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994006448A1 (en) * | 1992-09-16 | 1994-03-31 | The Scripps Research Institute | Human neutralizing monoclonal antibodies to respiratory syncytial virus |
WO1998019704A1 (en) * | 1996-11-01 | 1998-05-14 | Smithkline Beecham Corporation | Human monoclonal antibodies |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824307A (en) * | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
US6019980A (en) * | 1995-06-07 | 2000-02-01 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
US5811524A (en) * | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
-
2000
- 2000-05-16 CO CO00035406A patent/CO5280147A1/es not_active Application Discontinuation
- 2000-05-16 AR ARP000102352A patent/AR030019A1/es not_active Application Discontinuation
- 2000-05-18 EP EP00939304A patent/EP1178829A4/de not_active Withdrawn
- 2000-05-18 JP JP2000617922A patent/JP2002543822A/ja not_active Withdrawn
- 2000-05-18 AU AU54410/00A patent/AU5441000A/en not_active Abandoned
- 2000-05-18 WO PCT/US2000/013694 patent/WO2000069462A1/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994006448A1 (en) * | 1992-09-16 | 1994-03-31 | The Scripps Research Institute | Human neutralizing monoclonal antibodies to respiratory syncytial virus |
WO1998019704A1 (en) * | 1996-11-01 | 1998-05-14 | Smithkline Beecham Corporation | Human monoclonal antibodies |
Non-Patent Citations (1)
Title |
---|
See also references of WO0069462A1 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9963500B2 (en) | 2015-10-29 | 2018-05-08 | Merck Sharp & Dohme Corp. | Antibody neutralizing human respiratory syncytial virus |
US10072072B2 (en) | 2015-10-29 | 2018-09-11 | Merck Sharp & Dohme Corp. | Antibody neutralizing human respiratory syncytial virus |
US10323079B2 (en) | 2015-10-29 | 2019-06-18 | Merck Sharp & Dohme Corp. | Antibody neutralizing human respiratory syncytial virus |
US10358480B2 (en) | 2015-10-29 | 2019-07-23 | Merck Sharp & Dohme Corp. | Antibody neutralizing human respiratory syncytial virus |
US11008380B2 (en) | 2015-10-29 | 2021-05-18 | Merck Sharp & Dohme Corp. | Antibody neutralizing human respiratory syncytial virus |
US11566065B2 (en) | 2015-10-29 | 2023-01-31 | Merck Sharp & Dohme Llc | Antibody neutralizing human respiratory syncytial virus |
US11981726B2 (en) | 2015-10-29 | 2024-05-14 | Merck Sharp & Dohme Llc | Antibody neutralizing human respiratory syncytial virus |
Also Published As
Publication number | Publication date |
---|---|
JP2002543822A (ja) | 2002-12-24 |
AU5441000A (en) | 2000-12-05 |
WO2000069462A1 (en) | 2000-11-23 |
CO5280147A1 (es) | 2003-05-30 |
AR030019A1 (es) | 2003-08-13 |
EP1178829A4 (de) | 2005-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100490687B1 (ko) | Rsvf-단백질에특이적인고친화성인간모노클로날항체 | |
US8221759B2 (en) | Neutralizing monoclonal antibodies to respiratory syncytial virus | |
CA2703667C (en) | Anti-rsv g protein antibodies | |
WO2000069462A1 (en) | Human monoclonal antibody | |
KR20090088871A (ko) | 인간 메타뉴모바이러스를 중화시키는 인간 항체 | |
US20050019758A1 (en) | Human monoclonal antibodies | |
US20050175986A1 (en) | Human monoclonal antibody | |
CA2270288A1 (en) | Human monoclonal antibodies | |
WO2022258068A1 (zh) | 一种呼吸道合胞病毒的抗体及其应用 | |
JP2024522670A (ja) | 呼吸器合胞体ウイルスに対する抗体及びその使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20011206 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20050421 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20060719 |